Zusammenfassung
Zur Gruppe der Anästhetika gehören Substanzen mit sehr unterschiedlichen chemischen Strukturformeln (◘Abb. 2.1). Hierzu zählen Hydrocarbone (Chloroform, Halothan), Derivate des Ether (Isofluran, Desfluran, Sevofluran), Phenole (Propofol), Imidazolderivate (Etomidat, Dexmedetomidin), Phencyclidine (Ketamin), Steroide (Alphaxalone), Barbiturate (Thiopental), Benzodiazepine (Midazolam) und Edelgase (Xenon).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Antkowiak, B (2001) How do gerneral anaesthetis work? Neuro-wissenschaften 88:201–213
Cascorbi I (2006) Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 112:457–473
Daly AK (2009) Pharmacogenomics of anticoagulants: steps toward personal dosage. Genome Med 1:10
Drago A, De Ronchi D, Serretti A (2009) Pharmacogenetics of antidepressant response: an update. Hum Genomics 3:257–274
Drexler B, Grasshoff C, Rudolph U, Unertl K, Antkowiak B (2006) The GABA(A) receptor family : Possibilities for the development of better anesthetics. Anaesthesist 55:287–295
Eichelbaum M, Ingelman-Sundberg M, Evans WE (2006) Pharmacogenomics and individualized drug therapy. Annu Rev Med 57: 119–137
Franks NP (2006) Molecular targets underlying general anaesthesia. Brit J Pharmacol 147: S72–S81
Grasshoff C, Rudolph U, Antkowiak B (2005) Molecular and systemic mechanisms of general anaesthesia: the,multi-site and multiple mechanisms' concept. Curr Opin Anaesth 18:386–391
Hemmings HC, Akabas MH, Goldstein PA et al. (2005) Emerging molecular mechanisms of general anesthetic action. Trends Pharmacol Sci 26:503–510
Hughes AR, Spreen WR, Mosteller M et al. (2008) Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J 8:365–374
Kaiser R, Sezer O, Papies A et al. (2002) Patient-tailored anti-emetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20:2805–2811
Klotz U (2006) Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 44:297–302
La Du BN, Bartels CF, Nogueira CP, Arpagaus M, Lockridge O (1991) Proposed nomenclature for human butyrylcholinesterase genetic variants identified by DNA sequencing. Cell Mol Neurobiol 11:79–89
Liggett SB, Mialet-Perez J, Thaneemit-Chen S et al. (2006) A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA 103:11288–11293
Link E, Parish S, Armitage J et al. (2008) SLCO1B1 variants and statin-induced myopathy-a genomewide study. N EngI J Med 359:789–799
Loscher W, Delanty N (2009) MDR1/ABCB1 polymorphisms and multidrug resistance in epilepsy: in and out of fashion. Pharma-cogenomics 10:711–713
Lotsch J, Geisslinger G (2005) Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 11:82–89
Lotsch J, Geisslinger G (2006) Current evidence for a genetic modulation of the response to analgesics. Pain 121:1–5
Mariani G, Fasolo A, De Benedictis E, Gianni L (2009) Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol 6: 93–104
Nagele P, Zeugswetter B, Wiener C et al. (2008) Influence of methylenetetrahydrofolate reductase gene polymorphisms on homocysteine concentrations after nitrous oxide anesthesia. Anesthesiology 109:36–43
Niemi M (2007) Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8:787–802
Rau T, Wuttke H, Michels LM et al. (2009) Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin Pharmacol Ther 85:269–272
Robinson RL, Anetseder MJ, Brancadoro V et al. (2003) Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? Eur J Hum Genet 11:342–348
Rudolph U, Antkowiak B (2004) Molecular and neuronal substrates for general anaesthetics. Nature Rev Neuroscience 5: 709–720
Simon T, Verstuyft C, Mary-Krause M et al. (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N EngI J Med 360:363–375
Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB (2002) Synergistic polymorphisms of betal- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347:1135–1142
Sonner JM, Antognini JF, Dutton RC et al. (2003) Inhaled anesthetics and immobility: mechanisms, mysteries, and minimum alveolar anesthetic concentration. Anesth Anal 97:718–740
Steimer W, Zopf K, von Amelunxen S et al. (2005) Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 51:376–385
Urban BW (2002) Current assessment of targets and theories of anaesthesia. Br J Anaesth 89:165–183
Urban BW, Bleckwenn M (2002) Concepts and correlations relevant to general anaesthesia. Br J Anaesth 89:3–16
Urban BW, Bleckwenn M, Barann M (2006) Interactions of anesthetics with their targets: Non-specific, specific or both? Pharmacology therapeutics 111: 729–770
Yin T, Maekawa K, Kamide K et al. (2008) Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res 31:1549–1557
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Antkowiak, B., Cascorbi, I. (2011). Pharmakodynamik. In: Tonner, P.H., Hein, L. (eds) Pharmakotherapie in der Anästhesie und Intensivmedizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-79156-0_2
Download citation
DOI: https://doi.org/10.1007/978-3-540-79156-0_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-79155-3
Online ISBN: 978-3-540-79156-0
eBook Packages: Medicine (German Language)